Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience

被引:22
作者
Iskander, John [1 ]
Broder, Karen [1 ]
机构
[1] Ctr Dis Control & Prevent, US Publ Hlth Serv, Immunizat Safety Off, Off Chief Sci Officer, Atlanta, GA 30333 USA
关键词
influenza vaccine; pandemic; vaccine adverse events; vaccine safety;
D O I
10.1586/14760584.7.1.75
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Annual use of influenza vaccines represents the largest vaccine campaign conducted in the USA. Recent expansions in influenza vaccine recommendations suggest a move toward 'universal' vaccination strategies. Although a great deal of safety data has been accumulated, concerns remain regarding rare, serious adverse events following immunization. A proven association between the 1976-1977 swine influenza vaccine and Guillain-Barre syndrome halted that particular national vaccination campaign. Recently, annual influenza vaccines have been associated with novel adverse events, for example, oculorespiratory syndrome in Canada. Any vaccine used against an influenza strain of pandemic potential will have an incompletely described safety profile. Thus, the challenge of influenza vaccine safety is to detect new safety concerns that may arise during seasonal campaigns, while preparing vaccine safety systems for the timely detection of adverse events in the setting of a pandemic.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 53 条
[21]  
*FDA, VRBPAC BRIEF MAT 27
[22]  
Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1
[23]   Safety of the trivalent inactivated influenza vaccine among children - A population-based study [J].
France, EK ;
Glanz, JM ;
Xu, S ;
Davis, RL ;
Black, SB ;
Shinefield, HR ;
Zangwill, KM ;
Marcy, SM ;
Mullooly, JP ;
Jackson, LA ;
Chen, R .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2004, 158 (11) :1031-1036
[24]   Detection of adverse events: what are the current sensitivity limits during clinical development? [J].
Fritzell, B .
VACCINE, 2001, 20 :S47-S48
[25]   Guillain-Barre syndrome following influenza vaccination [J].
Haber, P ;
DeStefano, F ;
Angulo, FJ ;
Iskander, J ;
Shadomy, SV ;
Weintraub, E ;
Chen, RT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (20) :2478-2481
[26]  
Halsey Neal A, 2002, Semin Pediatr Infect Dis, V13, P205, DOI 10.1053/spid.2002.125864
[27]   Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old [J].
Hambidge, Simon J. ;
Glanz, Jason M. ;
France, Eric K. ;
McClure, David ;
Xu, Stanley ;
Yamasaki, Kristi ;
Jackson, Lisa ;
Mullooly, John P. ;
Zangwill, Kenneth M. ;
Marcy, S. Michael ;
Black, Steven B. ;
Lewis, Edwin M. ;
Shinefield, Henry R. ;
Belongia, Edward ;
Nordin, James ;
Chen, Robert T. ;
Shay, David K. ;
Davis, Robert L. ;
DeStefano, Frank .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (16) :1990-1997
[28]  
*I MED, 2003, IMMUNIZATION SAFETY
[29]  
Iskander John, 2005, Yale J Biol Med, V78, P265
[30]   Adverse events reported following live, cold-adapted, intranasal influenza vaccine [J].
Izurieta, HS ;
Haber, P ;
Wise, RP ;
Iskander, J ;
Pratt, D ;
Mink, C ;
Chang, SJ ;
Braun, MM ;
Ball, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (21) :2720-2725